RT Journal Article
SR Electronic
T1 Tocilizumab and mortality in hospitalised patients with covid-19. A systematic review comparing randomised trials with observational studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.23.21255815
DO 10.1101/2021.04.23.21255815
A1 Bélène Podmore
A1 Nawab Qizilbash
A1 Alessandra Lacetera
A1 Itziar Ubillos
A1 Kirsty Andresen
A1 Ana Roncero Martín
A1 Jara Majuelos-Melguizo
A1 Ana Cuñado Moral
A1 Marina Hinojosa Campos
A1 Jeffrey K Aronson
A1 Stuart Pocock
YR 2021
UL http://medrxiv.org/content/early/2021/04/26/2021.04.23.21255815.abstract
AB Objective To summarise and compare evidence from randomised controlled trials and observational studies of the effect of tocilizumab on in-hospital mortality in patients with covid-19.Design Systematic review and meta-analysis.Data sources Searches conducted in Embase and PubMed from July 2020 until 1 March 2021.Study Selection Observational studies and randomised controlled trials (RCTs) assessing in-hospital mortality in patients receiving tocilizumab compared with standard care or placebo.Data extraction The primary outcome was in-hospital mortality at 30 days. The risk of bias in observational studies was assessed using the ROBINS-I tool. A fixed effect meta-analysis was used to combine relative risks, with random effects and risk of bias as a sensitivity analysis.Results Of 5,792 publications screened for inclusion, eight RCTs and 35 observational studies were identified. The RCTs showed an overall relative risk reduction in in-hospital mortality at 30 days of 0.86 (95% CI 0.78 to 0.96) with no statistically significant heterogeneity. 23 of the observational studies had a severe risk of bias, 10 of which did not adjust for potential confounders. The 10 observational studies with moderate risk of bias reported a larger reduction in mortality at 30-days (relative risk 0.72, 95% CI 0.64 to 0.81) but with significant heterogeneity (P<0.01).Conclusion This meta-analysis provides strong evidence from RCTs that tocilizumab reduces the risk of mortality in hospitalised covid-19 patients. Observational studies with moderate risk of bias exaggerated the benefits on mortality two-fold and showed heterogeneity. Collectively observational studies provide a less reliable evidence base for evaluating treatments for covid-19.What is already known on this topicEarly case reports suggested that tocilizumab might produce clinical and biochemical improvement in covid-19. This was followed by observational studies using retrospective data, largely supporting clinicians’ impressions of benefit.This led to wider use of tocilizumab, despite failure to show benefit on all-cause mortality from early underpowered randomised controlled trials (RCTs) in severe covid-19. The RECOVERY trial, the largest trial, has recently shown clear overall benefit in hospitalised patients with covid-19.What this study addsThis meta-analysis provides strong evidence from RCTs that tocilizumab reduces the risk of mortality in hospitalised covid-19 patients.Observational studies with moderate risk of bias exaggerated the benefits on mortality by two-fold.Collectively observational studies provide a less reliable evidence base for evaluating treatments for covid-19.Competing Interest StatementOXON Epidemiology is a scientific service provider of observational research, pragmatic trials and meta-analysis to the pharmaceutical industry.Clinical Protocols https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=184089 Funding StatementThe real-time systematic review process was partially funded by GSK. GSK had no involvement in the analysis of the data, writing of the manuscript or the decision or timing of its submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval not required as this is a systematic review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for data sharing should be sent to the corresponding author.